| Lymphoma, Follicular
Gazyva vs Zevalin
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Gazyva vs Zevalin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZevalin has a higher rate of injection site reactions vs Gazyva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zevalin but not Gazyva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gazyva
Zevalin
At A Glance
IV infusion
Anti-CD20 monoclonal antibody
IV infusion
Single course
CD20-directed radioimmunotherapy
Indications
- Chronic Lymphocytic Leukemia
- Lymphoma, Follicular
- Lupus Nephritis
- Lymphoma, Follicular
Dosing
Chronic Lymphocytic Leukemia 100 mg IV on day 1 and 900 mg on day 2 of Cycle 1, then 1,000 mg on days 8 and 15 of Cycle 1, and 1,000 mg on day 1 of Cycles 2-6 (28-day cycles) in combination with chlorambucil.
Lymphoma, Follicular 1,000 mg IV on days 1, 8, and 15 of Cycle 1, then 1,000 mg on day 1 of Cycles 2-6 or 2-8 in combination with chemotherapy; responding patients continue on 1,000 mg monotherapy every 2 months for up to 2 years.
Lupus Nephritis 1,000 mg IV at initial infusion (Dose 1), at Week 2 (Dose 2), at Week 24 (Dose 3), at Week 26 (Dose 4), then 1,000 mg every 6 months thereafter, in combination with standard therapy.
Lymphoma, Follicular Day 1: rituximab 250 mg/m2 IV; Day 7, 8, or 9: rituximab 250 mg/m2 IV then Y-90 Zevalin 0.4 mCi/kg IV over 10 minutes (platelets >=150,000/mm3) or 0.3 mCi/kg IV over 10 minutes (platelets 100,000-149,000/mm3, relapsed or refractory); maximum dose 32 mCi; single course.
Contraindications
- Known hypersensitivity reaction (e.g., anaphylaxis) to obinutuzumab or any excipient
- Serum sickness with prior obinutuzumab use
—
Adverse Reactions
Most common (>=10%) Infusion-related reactions, neutropenia, thrombocytopenia, diarrhea, fatigue, upper respiratory tract infection, musculoskeletal pain
Serious Hepatitis B virus reactivation, progressive multifocal leukoencephalopathy, infusion-related reactions, hypersensitivity reactions including serum sickness, tumor lysis syndrome, infections, neutropenia, thrombocytopenia, disseminated intravascular coagulation
Postmarketing Serum sickness
Most common (>=5%) Cytopenias (thrombocytopenia, neutropenia, anemia, leukopenia, lymphopenia), fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, pyrexia
Serious Prolonged and severe cytopenias (thrombocytopenia, anemia, lymphopenia, neutropenia), MDS/AML, serious infusion reactions, severe cutaneous and mucocutaneous reactions
Postmarketing Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, exfoliative dermatitis, infusion site erythema and ulceration, radiation injury
Pharmacology
Obinutuzumab is a humanized anti-CD20 IgG1 monoclonal antibody with reduced fucose content that mediates B-cell lysis via immune effector cell engagement (ADCC and ADCP), direct intracellular death signaling, and complement activation; its reduced fucose content confers greater ADCC activity than rituximab.
Ibritumomab tiuxetan is a murine IgG1 kappa monoclonal antibody immunoconjugate that binds specifically to the CD20 antigen on pre-B and mature B lymphocytes and >90% of B-cell NHL; the covalently linked Y-90 chelate (tiuxetan) delivers targeted beta radiation, inducing cellular damage via free radical formation in CD20-expressing and neighboring cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gazyva
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
No coverage data available for Zevalin.
UnitedHealthcare
Gazyva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
No coverage data available for Zevalin.
Humana
Gazyva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
No coverage data available for Zevalin.
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Chronic Lymphocytic Leukemia (CLL)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GazyvaView full Gazyva profile
ZevalinView full Zevalin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.